Literature DB >> 12477702

Prognostic factors of CNS tumours in Neurofibromatosis 1 (NF1): a retrospective study of 104 patients.

Jean-Sébastien Guillamo1, Alain Créange, Chantal Kalifa, Jacques Grill, Diana Rodriguez, François Doz, Sébastien Barbarot, Michel Zerah, Marc Sanson, Sylvie Bastuji-Garin, Pierre Wolkenstein.   

Abstract

In addition to multiple peripheral neurofibromas, Neurofibromatosis 1 (NF1) predisposes to CNS tumours. Most of them are pilocytic astrocytomas, arise in children and are located in the optic pathways or in the brainstem. The majority are indolent, but factors predictive of poor prognosis have yet to be identified. Furthermore, the incidence and natural history of gliomas of a higher grade, arising in adults or involving other locations are largely unknown in NF1. In order to address these issues, we performed a retrospective study of 104 patients followed in seven French centres between 1982 and 2000. Inclusion criteria were a diagnosis of NF1, according to the National Institutes of Health criteria, and the presence of a CNS tumour, regardless of type, location or age of onset. The series included 88 children (age range 3 months to 17 years) and 16 adults (age range 19-52 years). The median follow-up was 5.6 years. One hundred and twenty-seven CNS tumours were observed in the 104 patients. Eighty-four (66%) were optic pathway tumours (OPT) and 43 (34%) extra-optic pathway tumours (extra-OPT) (brainstem: n = 21; other locations: n = 22). Twenty-one patients (20%) had multiple CNS tumours. OPT were symptomatic in 50 patients and extra-OPT in 19. Main clinical findings at presentation included visual loss (n = 29; 58%) and precocious puberty (n = 5; 10%) for OPT, increased intracranial pressure (n = 9; 48%) for extra-OPT. Fourteen out of the 27 symptomatic tumours with histology were pilocytic astrocytomas. The overall survival rate was 90% at 5 years (95% confidence interval 82-95%). Extra-optic location, tumour diagnosis in adulthood and symptomatic tumours were independent factors associated with shorter survival time (P < 0.05, Cox model). Radiotherapy for OPT was associated with vascular complications (ischaemic strokes) and growth hormone deficiency in 32 and 46% of patients, respectively. In conclusion, mortality is high in extra-OPT, particularly in adults, whereas OPT are only exceptionally life-threatening. Radiotherapy of OPT is associated with an important morbidity in NF1.

Entities:  

Mesh:

Year:  2003        PMID: 12477702     DOI: 10.1093/brain/awg016

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  84 in total

Review 1.  An update on the central nervous system manifestations of neurofibromatosis type 1.

Authors:  J Stephen Nix; Jaishri Blakeley; Fausto J Rodriguez
Journal:  Acta Neuropathol       Date:  2019-04-08       Impact factor: 17.088

Review 2.  Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes.

Authors:  D G R Evans; J M Birch; R T Ramsden; S Sharif; M E Baser
Journal:  J Med Genet       Date:  2005-09-09       Impact factor: 6.318

3.  Neurofibromatosis-1 regulates neuroglial progenitor proliferation and glial differentiation in a brain region-specific manner.

Authors:  Da Yong Lee; Tu-Hsueh Yeh; Ryan J Emnett; Crystal R White; David H Gutmann
Journal:  Genes Dev       Date:  2010-09-28       Impact factor: 11.361

4.  Neurofibromatosis: chronological history and current issues.

Authors:  João Roberto Antônio; Eny Maria Goloni-Bertollo; Lívia Arroyo Trídico
Journal:  An Bras Dermatol       Date:  2013 May-Jun       Impact factor: 1.896

5.  Genetic basis of neurofibromatosis type 1 and related conditions, including mosaicism.

Authors:  Eric Legius; Hilde Brems
Journal:  Childs Nerv Syst       Date:  2020-06-29       Impact factor: 1.475

Review 6.  Pediatric low-grade gliomas: how modern biology reshapes the clinical field.

Authors:  Guillaume Bergthold; Pratiti Bandopadhayay; Wenya Linda Bi; Lori Ramkissoon; Charles Stiles; Rosalind A Segal; Rameen Beroukhim; Keith L Ligon; Jacques Grill; Mark W Kieran
Journal:  Biochim Biophys Acta       Date:  2014-02-28

Review 7.  Pharmacotherapeutic management of pediatric gliomas : current and upcoming strategies.

Authors:  Trent R Hummel; Lionel M Chow; Maryam Fouladi; David Franz
Journal:  Paediatr Drugs       Date:  2013-02       Impact factor: 3.022

Review 8.  Using neurofibromatosis-1 to better understand and treat pediatric low-grade glioma.

Authors:  David H Gutmann
Journal:  J Child Neurol       Date:  2008-10       Impact factor: 1.987

Review 9.  Pediatric brain MRI in neurofibromatosis type I.

Authors:  Hans-J Mentzel; Jörg Seidel; Clemens Fitzek; Annegret Eichhorn; Susanna Vogt; Jürgen R Reichenbach; Felix Zintl; Werner A Kaiser
Journal:  Eur Radiol       Date:  2004-07-29       Impact factor: 5.315

10.  Gliomas in neurofibromatosis type 1: a clinicopathologic study of 100 patients.

Authors:  Fausto J Rodriguez; Arie Perry; David H Gutmann; Brian Patrick O'Neill; Jeffrey Leonard; Sandra Bryant; Caterina Giannini
Journal:  J Neuropathol Exp Neurol       Date:  2008-03       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.